Sophia Genetics SA: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Sophia Genetics SA Unternehmen

SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.

Sophia Genetics SA Informationen



BörsenkürzelSOPH

Name des UnternehmensSOPHiA GENETICS SA

IPO-datumJul 23, 2021

CEOCamblong (Jurgi)

Anzahl der mitarbeiter423

WertpapierartOrdinary Share

GeschäftsjahresendeJul 23

AddresseLa Piece 12

StadtROLLE

BörseNASDAQ OMX - NASDAQ BASIC

LandSwitzerland

PostleitzahlCH-1180

Telefon41216941060

Websitehttps://www.sophiagenetics.com/

BörsenkürzelSOPH

IPO-datumJul 23, 2021

CEOCamblong (Jurgi)

Führungskräfte von Sophia Genetics SA



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Jurgi Camblong, Ph.D.

Chief Executive Officer, Co-Founder, Director

3.02M

+11.25%

Mr. Ross J Muken

President

626.80K

+65.37%

Dr. Zhenyu Xu, Ph.D.

Chief Scientific Officer

517.79K

+18.11%

Dr. Vincent Ossipow, Ph.D.

Non-Executive Independent Director

469.35K

+5.44%

Mr. Troy M. Cox

Non-Executive Independent Chairman of the Board

275.24K

+14.89%

Mr. George A. Cardoza

Chief Financial Officer

198.05K

+53.82%

Mr. Didier Hirsch

Non-Executive Independent Director

184.71K

+27.49%

Dr. Philippe Menu, M.D., Ph.D.

Chief Medical Officer and Chief Product Officer

149.29K

+58.79%

Mr. Daan Van Well

Chief Legal and Compliance Officer

--

Ms. Manuela Da Silva Valente

Chief People Officer

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Jurgi Camblong, Ph.D.

Chief Executive Officer, Co-Founder, Director

3.02M

+11.25%

Mr. Ross J Muken

President

626.80K

+65.37%

Dr. Zhenyu Xu, Ph.D.

Chief Scientific Officer

517.79K

+18.11%

Dr. Vincent Ossipow, Ph.D.

Non-Executive Independent Director

469.35K

+5.44%

Mr. Troy M. Cox

Non-Executive Independent Chairman of the Board

275.24K

+14.89%

Mr. George A. Cardoza

Chief Financial Officer

198.05K

+53.82%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach RegionUSD

Name

Umsatz

Anteil

Rest of EMEA

25.65M

33.20%

France

11.32M

14.65%

United States

10.87M

14.07%

Italy

10.80M

13.98%

Spain

6.03M

7.80%

Andere

12.60M

16.30%

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: 13 hours ago

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Alychlo NV

9.74%

Generation Investment Management LLP

9.46%

aMoon Fund

7.68%

Akre Capital Management, LLC

5.18%

Balderton Capital (UK) LLP

4.60%

Andere

63.35%

Aktionäre

Anteil

Alychlo NV

9.74%

Generation Investment Management LLP

9.46%

aMoon Fund

7.68%

Akre Capital Management, LLC

5.18%

Balderton Capital (UK) LLP

4.60%

Andere

63.35%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor/Hedge Fund

16.25%

Venture Capital

12.29%

Family Office

9.79%

Investment Advisor

8.60%

Individual Investor

8.35%

Hedge Fund

0.92%

Bank and Trust

0.37%

Research Firm

0.10%

Pension Fund

0.04%

Andere

43.29%

Institutionelle Beteiligung



Aktualisiert: Wed, Apr 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

89

27.73M

38.63%

-11.89M

2025Q4

82

26.92M

39.67%

-12.60M

2025Q3

76

26.89M

39.64%

-8.96M

2025Q2

89

36.69M

54.29%

-200.15K

2025Q1

93

36.63M

54.82%

-389.48K

2024Q4

93

32.50M

49.36%

-965.83K

2024Q3

91

34.60M

52.08%

+657.87K

2024Q2

92

32.44M

48.93%

+1.33M

2024Q1

93

31.91M

48.51%

+375.11K

2023Q4

91

30.61M

46.76%

-676.23K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Alychlo NV

6.99M

9.76%

--

Feb 15, 2026

Generation Investment Management LLP

6.79M

9.47%

--

Feb 15, 2026

aMoon Fund

5.51M

7.69%

--

Feb 15, 2026

Akre Capital Management, LLC

3.72M

5.19%

--

Dec 31, 2025

Balderton Capital (UK) LLP

3.30M

4.61%

-60.64K

-1.80%

Dec 31, 2025

Camblong (Jurgi)

2.68M

3.74%

-4.49K

-0.17%

Mar 19, 2026

Banque Pictet & Cie S.A.

2.21M

3.08%

--

Dec 31, 2025

Principal Global Investors (Equity)

1.40M

1.95%

+8.23K

+0.59%

Dec 31, 2025

Alta Wealth Advisors LLC

1.41M

1.97%

--

Dec 31, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares Health Innovation Active ETF

0%

Fidelity Nasdaq Composite Index ETF

0%

iShares Health Innovation Active ETF

Anteil0%

Fidelity Nasdaq Composite Index ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten